Midostaurin
Midostaurin
Definition
A synthetic indolocarbazole multikinase inhibitor with potential antiangiogenic and antineoplastic activities. Midostaurin inhibits protein kinase C alpha (PKCalpha), vascular endothelial growth factor receptor 2 (VEGFR2), c-kit, platelet-derived growth factor receptor (PDGFR) and FMS-like tyrosine kinase 3 (FLT3) tyrosine kinases, which may result in disruption of the cell cycle, inhibition of proliferation, apoptosis, and inhibition of angiogenesis in susceptible tumors.
Also known as CGP 41251, CGP41251, MIDOSTAURIN, N-Benzoyl-Staurosporine, N-Benzoylstaurosporine, PKC 412, PKC-412, PKC412, Rydapt — per NCIT
Also identified as
- ATC L01EX10 per RXNORM
- NCIT NCIT:C1872 per NCIT
- SCTID 763613005 per RXNORM
- SCTID 763614004 per RXNORM
- UNII ID912S5VON per RXNORM
Indications
| Disease | Relation | Source |
|---|---|---|
| Acute myeloid leukemia | may treat | MEDRT · Public domain (U.S. Government work) |
| Hematopoietic and lymphoid system neoplasm | may treat | MEDRT · Public domain (U.S. Government work) |
Organ Effects
| Organ | Side effect / interaction | Source |
|---|---|---|
| Bone marrow | may treat a disease of this organ | DERIVED · CC BY 4.0 |
1 entry above is marked DERIVED: Atlas Médico inferred it by combining two sourced claims, and no source asserts this link directly. Treat it as a navigation aid, not as a clinical statement.